Serological markers facilitate the diagnosis of Crohn’s disease

References

• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management[J]. J Crohn’s Colitis. 2016;11(1):3–25.
   Google Scholar
• ACG clinical guideline: management of Crohn’s disease in adults[J].
   Google Scholar
• Kappelman MD, Rifas Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults[J]. Gastroenterology. 2008;135(6):1907–1913.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease[J]. Inflamm Bowel Dis. 2012;18(3):496–505.
   PubMed Web of Science ®Google Scholar
• Nguyen VQ, Jiang D, Hoffman SN, et al. Impact of diagnostic delay and associated factors on clinical outcomes in a U.S. inflammatory bowel disease Cohort[J]. Inflamm Bowel Dis. 2017;23(10):1825–1831.
   PubMed Web of Science ®Google Scholar
• Kingsley MJ, Abreu MT. A personalized approach to managing inflammatory bowel disease[J]. Gastroenterol Hepatol. 2016;12(5):308–315.
   Google Scholar
• Gisbert JP, Chaparro M. Clinical usefulness of proteomics in inflammatory bowel disease: a comprehensive review[J]. J Crohn’s Colitis. 2019;13(3):374–384.
   Google Scholar
• Bennike T. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies[J]. World J Gastroenterol. 2014;20(12):3231.
   PubMed Web of Science ®Google Scholar
• Tamboli CP, Doman DB, Patel A. Current and future role of biomarkers in Crohn’s disease risk assessment and treatment[J]. Clin Exp Gastroenterol. 2011;4:127–140.
   PubMedGoogle Scholar
• Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease[J]. Gastroenterology. 2006;131(2):366–378.
   PubMed Web of Science ®Google Scholar
• Israeli E. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease[J]. Gut. 2005;54(9):1232–1236.
   PubMed Web of Science ®Google Scholar
• Walker LJ, Aldhous MC, Drumondous HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutations[J]. Clin Exp Immunol. 2004;135(3):490–496.
   PubMed Web of Science ®Google Scholar
• Birimberg-Schwartz L, Wilson DC, Kolho K, et al. pANCA and ASCA in children with IBD-Unclassified, Crohn’s colitis, and ulcerative colitis—a longitudinal report from the IBD Porto group of ESPGHAN[J]. Inflamm Bowel Dis. 2016;22(8):1908–1914.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, et al. update of the EULAR recommendations for the management of Behçet’s syndrome[J]. Ann Rheum Dis. 2018;2018:2018–213225.
   Google Scholar
• Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis screening, testing, and treatment of U.S. health care personnel: recommendations from the national tuberculosis controllers association and CDC, 2019[J]. MMWR Morb Mortal Wkly Rep. 2019;68(19):439–443.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders[J]. J Crohn’s Colitis. 2017;11(6):649–670.
   Google Scholar
• Perlemuter G, Guillevin L, Legman P, et al. Cryptogenetic multifocal ulcerous stenosing enteritis: an atypical type of vasculitis or a disease mimicking vasculitis[J]. Gut. 2001;48(3):333–338.
   PubMed Web of Science ®Google Scholar
• Paul S, Boschetti G, Rinaudo-Gaujous M, et al. Association of anti-glycan antibodies and inflammatory bowel disease course[J]. J Crohn’s Colitis. 2015;9(6):445–451.
   Google Scholar
• Zhang S, Luo J, Wu Z, et al. Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behcet’s disease[J]. Clin Transl Gastroenterol. 2018;9(2):e133.
   PubMedGoogle Scholar
• Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour[J]. Gut. 2007;56(10):1394–1403.
   PubMed Web of Science ®Google Scholar
• Joossens SCJLC. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. [J]. Gut. 2006;55(11):1667–1669.
   PubMed Web of Science ®Google Scholar
• Tung CC, Wong JM, Lee WC, et al. Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn’s disease[J]. J Gastroenterol Hepatol. 2014;29(4):723–729.
   PubMed Web of Science ®Google Scholar
• Ippoliti A, Devlin S, Mei L, et al. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn’s disease[J]. Inflamm Bowel Dis. 2010;16(8):1279–1285.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression[J]. Am J Gastroenterol. 2006;101(2):360–367.
   PubMed Web of Science ®Google Scholar
• Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients[J]. Am J Gastroenterol. 2006;101(3):645–652.
   PubMed Web of Science ®Google Scholar